ude statements regarding the intended enrollment of the Phase II clinical trial for cognitive dysfunction in multiple sclerosis, the potential results of the trial and the funding for the 15-center relapses in multiple sclerosis clinical trial. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Adeona's forward-looking statements include, among others, a failure to complete the intended enrollment, a failure of the clinical trial to provide desired results, our failure to successfully commercialize a new oral therapy for cognitive dysfunction in multiple sclerosis, an inability to complete the trials with the current funding and other factors described in Adeona's report on Form 10-K for the year ended December 31, 2010 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Adeona undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
For further information, please contact Adeona at (734) 332-7800, Ext. 22.
[i] Sicotte, Liva, Klutch, Pfeiffer, Bouvier, Odesa, Wu, Voskuhl, Treatment of multiple sclerosis with the pregnancy hormone estriol, Ann Neurol. 2002 Oct;52(4):421-8.
[ii] Gold and Voskuhl, Estrogen treatment in multiple sclerosis, J Neurol Sci. 2009 Nov 15;286(1-2):99-103. Epub 2009 Jun 18.
Page: 1 2 3 4 5 Related biology technology :1
|SOURCE Adeona Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Adeona Appoints Julie A. Caudill, B.B.A., Vice President of Finance and Corporate Controller2
. Adeonas Multiple Sclerosis Clinical Trial Receives $1,594,553 Grant3
. Adeona Announces Positive Alzheimers Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy4
. Adeona CEO to Present at the NYC Medtech Forum5
. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results6
. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance7
. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL6258
. Anesiva Announces Second Quarter 2008 Financial Results and Update9
. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 200810
. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 200811
. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results